Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Safety Study of Amifampridine Phosphate in SMA Type 3
NCT03819660Phase 2Terminated
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifampridine in Spinal muscular atrophy type 3 (SMA3). Primary endpoint: Long-term Safety and Tolerability of Amifampridine at 18 months. Started Mar 2019; status: terminated.
02
Drugs
amifampridine
03
Conditions
Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on NCT03819660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819660.